Skip Navigation LinksHome > September 2011 - Volume 6 - Issue 5 > Targeting HIV-1 innate immune responses therapeutically
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e32834970d8
Innate immunity: Edited by William A. Paxton and Teunis B.H. Geijtenbeek

Targeting HIV-1 innate immune responses therapeutically

Ellegård, Rada; Shankar, Esaki M.; Larsson, Marie

Free Access
Article Outline
Collapse Box

Author Information

Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

Correspondence to Marie Larsson, PhD, Division of Molecular Virology, Linköping University, Lab 1, Plan 13 HU, 581 85 Linköping, Sweden Tel: +46 10 1031055; e-mail:

Collapse Box


Purpose of review: The early stage of HIV-1 infection is when the virus is most vulnerable, and should therefore offer the best opportunity for therapeutic interventions. This review addresses the recent progress in the understanding of innate immune responses against HIV-1 with focus on the potential targets for prevention of viral acquisition, replication and dissemination.

Recent findings: Research indicates that the host-derived factor trappin-2/elafin is protective against HIV, whereas semen-derived enhancer of viral infection and defensins 5 and 6 enhance viral transmission. Further, studies suggest that stimulation of TLR4 and inhibition of TLR7–9 pathways may be HIV suppressive. The regulation and function of viral restriction factors tetherin and APOBEC3G have been investigated and a molecule mimicking the premature uncoating achieved by TRIM5α, PF74, has been identified. Chloroquine has been shown to inhibit plasmacytoid dendritic cell activation and suppress negative modulators of T-cell responses. Blockade of HMBG1 has been found to restore natural-killer-cell-mediated killing of infected dendritic cells, normally suppressed by HIV-1. Interestingly, when used as adjuvants, EAT-2 and heat shock protein gp96 reportedly enhance innate immune responses.

Summary: Several targets for innate immunity-mediated therapeutics have been identified. Nonetheless, more research is required to unveil their underlying mechanisms and interactions before testing these molecules in clinical trials.

Back to Top | Article Outline


The innate immune system is the first line of defense against HIV-1 and is crucial for the initial antiviral activity which reduces viral replication and protects surrounding cells from infection, as well as for the development of appropriate adaptive immune responses [1]. To date, the vast majority of HIV-1 research has focused on the adaptive immunity in order to formulate an effective vaccine. Due to the limited success of the recent vaccine candidates [2,3], research on innate-mediated antiviral immunity is on the increase.

Following mucosal sexual transmission of HIV-1, viral RNA initially remains undetectable in the peripheral blood. Studies in the SIV-macaque model have demonstrated that infection may be initiated in dendritic cells and Langerhans cells [4], followed by establishment in certain CD4+ T-cell populations (40–50 cells) approximately 3–4 days after exposure [5,6]. When viral RNA, that is, HIV-1, appears in the circulation (approximately 7 days later), the CD4+ T cells in the gut are substantially depleted [7] and a persistent infection has already been established in the lymphatic tissue [8]. This implies that the early stage of infection is when HIV-1 is most vulnerable, and should offer the best opportunity for rapid therapeutic intervention. In addition, HIV-1 elite controllers frequently lack the standard pathognomonic features of primary infection [9] and can control viral replication before the onset of adaptive immune responses [10]. This control is not because of the intrinsic resistance of CD4+ T cells to infection [11••] and suggests the potential of innate immunity as the key determinant of HIV disease progression.

Recent findings with respect to innate-mediated immune responses against HIV-1 could lead to the development of potent microbicides/antiviral agents that can successfully prevent viral acquisition, replication and dissemination as well as valuable insights into possible adjuvants that can shape innate immune responses to enhance the effect of future vaccines.

Back to Top | Article Outline

Microbicides in genital and rectal mucosa

In addition to posing a mechanical barrier to viral entry, the host genital and rectal mucosa offers a plethora of microbicides that can prevent infection and viral replication, as well as decrease inflammation (Fig. 1) [12••,13•,14•,15–17,18•]. As existing inflammation in the mucosa, due to HIV/SIV itself or a preexisting coinfection such as HSV [19,20], aids in establishment and expansion of HIV/SIV, the anti-inflammatory properties of microbicides at mucosal sites may prevent viral dissemination. Although none of the synthetic microbicides that have completed phase III clinical trials appear to offer good protection correlates [21,22], research on novel antimicrobial molecules should generate better results. A serine protease inhibitor produced by epithelial cells in the human female reproductive tract, trappin-2/elafin, has been identified to possess both anti-inflammatory and HIV-inhibitory activities [12••], and has been associated with protection against HIV-1 acquisition [23].

Figure 1
Figure 1
Image Tools

Not all secreted antimicrobials are protective, mucosal defensins 5 and 6 increase HIV infectivity in vitro and have been proposed to have partially caused the failure of some microbicide candidates in trials [13•]. Semen-derived enhancer of viral infection (SEVI), a type of amyloid aggregates found in semen, enhance viral attachment to target cells and their levels have been correlated to HIV infectivity [14•]. In addition, HIV has developed mechanisms to exploit the human complement system by incorporating regulators of complement activation into its envelope while budding from infected host cells [15], leading to enhanced infection and transmission from dendritic cells to T cells [16]. The inactivated complement fragments present on the viral surface might be involved in the induction of tolerance and immune suppression [24,25]. Of note, frequently exposed uninfected commercial sex workers expressed less complement component C3 in their genital mucosa compared with HIV-infected sex workers and uninfected low-risk groups [26]. In the light of these findings, the effects of complement opsonization on infectivity and induction of innate immune responses are important to investigate when developing therapeutics and vaccines.

In order to successfully identify or develop agents with HIV-protective properties, the great complexity of innate-immunity regulation in human mucosa must be taken into consideration. Dissecting the roles and mechanisms of action of individual innate factors combined with a greater understanding of how they interact with and are influenced by hormonal fluctuations [27], coinfections [17,18•], as well as the effect of semen on the mucosal milieu and HIV susceptibility will be challenging, will be valuable tools in the development of prevention modalities.

Box 1
Box 1
Image Tools
Back to Top | Article Outline

Induction of innate immune responses through Toll-like receptor pathways

Activation of pattern recognition receptors (PRRs) of the innate immune system is crucial for early antiviral defense, which includes production of interferons (IFNs) and interferon-inducible factors (Fig. 2) [28•,29,30•,31••,32••,33•]. The most studied class of PRRs, Toll-like receptors (TLRs) have been examined to evaluate whether their signaling can be exploited to generate effective vaccines and therapeutic interventions. Although all TLRs (1–10) can be found in the human mucosa, TLR3, 4, 7, 8 and 9 preferentially induce IFN production, and thereby exhibit antiviral activity. Research showing that HIV has developed mechanisms to evade triggering TLR-induced responses [34••,35•] supports their potential as targets for innate-mediated interventions.

Figure 2
Figure 2
Image Tools

The major concern with TLRs is their association with inflammation and other immunoregulatory factors that may favor HIV replication and dissemination. Inducing high levels of IFN to provide potent innate antiviral immunity, but bypassing the induction of inflammation and recruitment of leukocytes to sites of infection is a challenge. Insights into which TLRs are suitable targets for HIV prevention have been generated by studies on mucosal commensal bacteria and their effect on HIV susceptibility. One study showed that in macrophages, whereas bacteria with HIV-suppressive effects preferentially stimulated TLR4, the ones that enhanced HIV replication stimulated TLR2 [28•]. These results are consistent with effects seen in dendritic cells following TLR4 and TLR2 stimulation [29]. Furthermore, HIV inhibition through targeting TLR4 utilizing prothymosin-α, a naturally occurring TLR4 ligand produced by CD8+ T cells, potently suppressed HIV after entry into macrophages via production of type-I IFN [30•].

Stimulation of TLR3, which has been shown to act independently of inflammation [36], in macrophages through dsRNA (poly I:C) significantly inhibited HIV infection and replication by inducing type-I IFN inducible factors such as apolipoprotein B mRNA-editing enzyme 3G (APOBEC3G) and tetherin [37•]. However, the suitability of TLR3 ligands for HIV suppression remains dubious as they also have been shown to increase Langerhans cell maturation and HIV transmission [38].

Although some results indicate that signaling through TLR9 may be HIV suppressive [39•], most studies claim that stimulation of TLR7 and TLR9 induces inflammation and augments HIV replication and spread [31••,40]. Recent results showed that phosphorothioate 2′ deoxyribose oligomers, which specifically block these TLRs, significantly inhibited the infection of peripheral blood mononuclear cells (PBMCs) by HIV [31••]. In addition, the oligomers did not appear to be toxic in vitro[31••], making them viable microbicide candidates that merit further investigation.

A possible means of avoiding inflammation resulting from TLR activation is through the use of miRNAs, which may reduce the expression of TLRs or inhibit their downstream signaling. Let-7e and miR-105 have been shown to decrease the expression of TLR4 [41] and TLR2 [42], respectively, whereas miR-155 has been reported to inhibit key proteins in downstream TLR signaling [43]. However, despite the potential advances in molecular medicine this approach may not be optimal for HIV therapy as blocking TLR signaling may impair responses to other infections and/or cell functions such as antigen presentation [44••].

In myeloid dendritic cells (mDCs), corresponding to tissue dendritic cells, HIV achieved productive infection by exploiting TLR8 signaling in combination with the C-type lectin DC-SIGN, as blocking either pathway abrogated replication and prevented HIV transmission [32••]. This mechanism could potentially be exploited to prevent infection and viral dissemination.

A study in mouse dendritic cells showed that expression of A20, an inducible feedback inhibitor of retinoid-inducible gene-1 (RIG-1), and TLR signaling pathways, inhibited robust mucosal and systemic HIV-specific cellular and humoral responses [45•]. When A20 expression was silenced it enhanced dendritic cell's ability to home to gut-associated lymphoid tissues following systemic administration, as well as inhibiting the expression of gut-homing receptors on T and B cells [45•], which would be beneficial in a HIV vaccine.

Back to Top | Article Outline

Viral restriction factors

Viral restriction factors are constitutive or IFN-induced components of the innate immune response interfering with different stages of viral replication (Fig. 3) [46,47••–49••,50,51,52•,53•,54]. Three classes of restriction factors affecting lentiviruses have been identified: cytidine deaminases, such as APOBEC3G, which induce lethal hypermutations in the viral genome; tripartite motif-containing factor (TRIM) proteins, which may affect stages of the replication cycle such as uncoating and budding; and tetherin, which prevents mature HIV particles from being released from infected cells [55,56].

Figure 3
Figure 3
Image Tools

APOBEC3G inhibits reverse transcription and integration events during the course of HIV's life cycle. However, upon infecting a cell, the viral protein Vif targets APOBEC3G for proteasomal degradation, abrogating or severely diminishing its antiviral functions [50]. In addition, APOBEC3G is thought to be able to exert antiviral activity only if it is incorporated into the viral particles [57]. Nevertheless, upregulation of APOBEC3G expression in PBMCs by immunizing macaques with SIV antigens and CCR5 peptides linked to a 70-kDa heat-shock protein (HSP) offered protection from subsequent SIV challenge [51]. There is some concern that instead of decreasing HIV infectivity in patients, APOBEC3G upregulation may raise mutagenic activity to a level that is insufficient to render the virions noninfectious and instead aid in the evolution of drug-resistant phenotypes [52•,53•,58•]. Although recent studies have shed some light on the regulatory mechanisms of ABOBEC3G [59•,60•], it is likely that development of novel probes and research reagents will be necessary in order to dissect the mechanisms that determine what precise role APOBEC3G plays in infected cells.

Although TRIM5α is responsible for the complete block of HIV replication in Old World monkeys, its human homolog has no HIV-suppressive properties. However, the molecule PF74 has been found to prematurely uncoat HIV in target cells, by mimicking the activity of simian TRIM5α [48••]. Another IFN-induced TRIM protein which inhibits viral assembly, TRIM22, has been associated with significantly lower risk of HIV acquisition and lower viral loads or higher CD4+ T-cell counts during primary infection [49••], although its exact mechanisms of action and regulation have not yet been fully elucidated.

Ever since the discovery of its viral restriction properties in 2008 [54,61], the IFN-α-induced protein tetherin has been intensively studied. Tetherin is constitutively expressed by the plasmacytoid dendritic cells (pDCs) and restricts productive HIV cell–cell transmission [62•], as well as participating in an important negative feedback loop limiting IFN responses to viral infections [63]. The HIV-1 protein Vpu interferes with tetherin [54]. The fact that HIV-1 has developed highly specific tools to antagonize tetherin clearly suggests that this host restriction factor could be a potent inhibitor of viral replication in vivo.

In contrast to the factors discussed above, the peptidyl-propyl isomerase cyclophilin A (CypA) protein expressed by host cells helps in HIV replication, by binding the HIV capsid protein p24 [46]. It has recently been discovered that a CypA inhibitor, Debio-025, blocks this interaction and reduces viral replication [47••], and may therefore have therapeutic potential.

Back to Top | Article Outline

Dendritic cells and natural killer cells

pDCs produce more type-I IFN in response to HIV than any other cell type in the body and subsequently activate mDCs and natural killer (NK) cells as well as inducing adaptive immune responses [64•,65,66••,67••,68•,69•,70] (Fig. 4). IFN-α is both beneficial, as it inhibits virus replication early during infection, and harmful, as it contributes to chronic immune activation that drives progression to AIDS [71]. Blood pDCs and mDCs are hyperresponsive in HIV-infected individuals, indicating that they play an important role in chronic immune activation [72•]. It is hypothesized that some of the detrimental effects of chronically activated dendritic cells and extended IFN production are mediated by indoleamine 2,3-dioxygenase (IDO) which leads to disruption of Th17/Treg T-cell balance [64•,65]. In-vitro studies show that when IFN-α is blocked using chloroquine, an antimalaria drug, pDC activation is inhibited and negative modulators of T-cell responses, such as IDO and programmed death ligand-1 (PDL-1) are suppressed [66••]. The use of chloroquine along with antiretroviral therapy may interfere with chronic immune activation in infected individuals.

Figure 4
Figure 4
Image Tools

Although the role of pDCs in later stages of HIV infection is not clearly understood, studies show that while HIV-infected subjects with progressive disease have a significant decline in pDCs over time, elite suppressors maintain high levels of these cells [73], indicating that they are important factors in the innate immune response. A novel association between polymorphisms in interferon-regulatory factor-7 (IRF7), a master regulator of IFN-α, and the ability of pDCs to produce IFN-α in response to HIV-1 has recently been described [74•]. Further insight into the early events in primary infection and the underlying mechanisms behind elite controller's ability to maintain pDC levels and functions will assume paramount importance to achieve elite control of HIV replication.

NK cells interact with T cells and dendritic cells to shape the magnitude and quality of adaptive immune responses [70]. This ‘editing process’ is impaired when the dendritic cells are infected with HIV-1, and novel findings show that this occurs because of the upregulation of two antiapoptotic molecules, cellular FLICE-inhibitory protein (c-FLIP) and cellular inhibitor of apoptosis 2 (c-IAP2) [67••]. This upregulation is reportedly controlled by high-mobility group box1 (HMGB1), a key mediator of natural killer cell–dendritic cell crosstalk. Blockade of c-FLIP and c-IAP2 or HMGB1 restored NK cell's capability to destroy HIV-infected dendritic cells [67••]. These mechanisms could possibly be targeted to eliminate infected dendritic cells early in HIV infection.

NK cells play an important role in the control of HIV infection by lysing infected cells [70]. The exact mechanisms that mediate the recognition of HIV-infected cells are not known, detection could either occur directly, through receptor-mediated interactions that have not yet been identified, or indirectly by antibody-mediated crosslinking of CD16, an Fc receptor for IgG [75]. HIV Vpu has recently been shown to inhibit surface expression of NTB-A (NK-cell, T-cell and B-cell antigen) in infected cells, thus protecting the cells from lysis [69•]. Also, the effects that HIV infection exerts on NK-cell functions remain to be elucidated as alteration in cell phenotype but cell levels has not been reported [76]. Identifying the receptors responsible for NK-cell recognition of HIV and the effects HIV viremia exerts on NK-cell functions remains a key research area. One study found that HIV progressors overexpressed NKp44L on their CD4+ T cells as compared with HIV controllers and healthy donors, causing autologous NK lysis, and that this lysis was abrogated after treatment with anti-NKp44L mAb [68•]. Such research on the specific functional activity of NK cells may have important implications for the design of new anti-HIV therapeutical strategies.

Manipulating dendritic cell, macrophage and NK-cell responses may be useful strategies in vaccine development. In a mouse model, coexpression of HIV antigens and EWS-FLI1-activated transcript 2 (EAT-2), an adapter protein that leads to activation of the signaling lymphocytic activation molecule (SLAM) receptors on dendritic cells and macrophages, enhanced the induction of antigen-specific cellular immune responses and facilitated bystander activation of NK, NKT, B and T cells [77•]. Seeing that the EAT-2 adapter is conserved in both mice and humans, human vaccination strategies that specifically facilitate SLAM signaling may improve vaccine potency. The use of a genetically engineered, secreted form of heat shock protein gp96 (HSP gp96), an endoplastic-reticulum-resident chaperone, as an adjuvant in a SIV-macaque model showed some success in the induction of high levels of antigen-specific CD8+ T-cell and memory responses in rectal and vaginal mucosa [78•].

Back to Top | Article Outline


Mounting evidence suggests that innate immune responses determine susceptibility as well as disease progression in HIV infection. The goal for therapeutics targeting innate factors is a high level of protection or optimally a block of infection. Given that a recent trial has shown that mucosally applied inhibitors can confer protection from HIV-1 infection [79••], the application of potent drugs targeting innate factors present in the genital mucosa is a viable prospect for inhibiting HIV infection.

Back to Top | Article Outline


This work has been supported by the grant AI52731 from the Swedish Research Council, The Swedish Physicians against AIDS Research Foundation, The Swedish International Development Cooperation Agency, SIDA SARC, VINNMER for Vinnova, Linköping University Hospital Research Fund, CALF and The Swedish Society of Medicine.

Back to Top | Article Outline
Conflicts of interest

None declared.

Back to Top | Article Outline

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

* • of special interest

* •• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 448).

Back to Top | Article Outline


1. Chang J, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010; 202:S297–S301.

2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209–2220.

3. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661–1671.

4. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087–6095.

5. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286:1353–1357.

6. Miller C, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217–9227.

7. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708–11717.

8. Chun T, Engel D, Berrey M, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869–8873.

9. Altfeld M, Addo M, Rosenberg E, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581–2591.

10. Goujard C, Chaix M, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is ‘HIV controller’ status established. Clin Infect Dis 2009; 49:982–986.

11••. Rabi S, O’Connell K, Nikolaeva D, et al. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 2011; 85:979–986.

This study has proven that elite control of HIV infection is not because of the intrinsic resistance of CD4+ T cells to HIV entry and infection.

12••. Ghosh M, Shen Z, Fahey J, et al. Trappin-2/Elafin: a novel innate antihuman immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2010; 129:207–219.

This study introduces a novel promising HIV-inhibitory molecule, which may hold therapeutic potentials if studied further.

13•. Ding J, Rapista A, Teleshova N, et al. Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides. J Innate Immunol 2011; 3:208–212.

This study illustrates the difficulty of developing effective mucosally applied therapeutics because of complexity of the mucosal environment, especially in the presence of co-infections.

14•. Kim K, Yolamanova M, Zirafi O, et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology. 2010; 7:55.

This study describes how one of the many factors present in semen has a high impact on HIV infectivity.

15. Stoiber H, Pruenster M, Ammann C, Dierich M. Complement-opsonized HIV: the free rider on its way to infection. Mol Immunol 2005; 42:153–160.

16. Bouhlal H, Chomont N, Requena M, et al. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007; 178:1086–1095.

17. Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol 2011; 65:89–98.

18•. De Jong M, de Witte L, Taylor M, Geijtenbeek T. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol 2010; 185:1633–1641.

This study identifies Langerhans cell maturation induced by HSV-2 via TLR3 signaling as the one potential mechanism leading to increased HIV susceptibility in HSV-2 infected individuals.

19. Li Q, Estes J, Schlievert P, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034–1038.

20. Freeman E, Weiss H, Glynn J, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73–83.

21. Feldblum P, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474.

22. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008; 3:e3784.

23. Iqbal S, Ball T, Levinson P, et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:1669–1677.

24. Sohn J, Bora P, Suk H, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003; 9:206–212.

25. Verbovetski I, Bychkov H, Trahtemberg U, et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med 2002; 196:1553–1561.

26. Burgener A, Boutilier J, Wachihi C, et al. Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteasome Res 2008; 7:4446–4454.

27. Wira C, Fahey J, Ghosh M, et al. Hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2010; 63:544–565.

28•. Ahmed N, Hayashi T, Hasegawa A, et al. Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4. J Gen Virol 2010; 91:2804–2813.

This study examines how TLR stimulation by commensal bacteria affects HIV susceptibility, although performed on a single cell type.

29. Thibault S, Fromentin R, Tardif M, Tremblay M. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 2009; 6:42.

30•. Mosoian A, Teixeira A, Burns C, et al. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci USA 2010; 107:10178–10183.

This study describes a molecule naturally produced by CD8+ T cells that acts as a TLR4 ligand and stimulates type-I IFN production to potently suppress HIV-1 after entry into cells.

31••. Fraietta J, Mueller Y, Do D, et al. Phosphorothioate 2′ deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1. Antimicrob Agents Chemother 2010; 54:4064–4073.

This study shows that HIV can be suppressed by inhibiting TLR7 and TLR9 signaling. The inhibitor used did not appear to be toxic in vitro, and may therefore have therapeutic potential if studied further.

32••. Gringhuis S, van der Vlist M, van den Berg L, et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010; 11:419–426.

This study sheds light on a mechanism exploited by HIV to achieve productive infection in dendritic cells, which could possibly be targeted therapeutically, as the inhibitor used, GW5074, does not appear to be toxic.

33•. Lu J, Pan Q, Rong L, et al. The IFITM proteins inhibit HIV-1 infection. J Virol 2011; 85:2126–2137.

This study suggests that induction of IFITM proteins through type-I IFN is an important innate mechanism limiting HIV infection by interfering with viral entry.

34••. Manel N, Hogstad B, Wang Y, et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467:214–217.

This study shows that HIV has developed evasion strategies to avoid the triggering of TLR-mediated responses in dendritic cells, which suggests that targeting TLRs may be a viable approach for HIV intervention.

35•. Yan N, Regalado-Magdos A, Stiggelbout B, et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010; 11:1005–1013.

This study describes the mechanism whereby HIV avoids triggering of TLR responses in dendritic cells. Further elucidation of this mechanism may lead to HIV-intervention strategies.

36. Ashkar A, Yao X, Gill N, et al. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004; 190:1841–1849.

37•. Zhou Y, Wang X, Liu M, et al. A critical function of toll-like receptor-3 in the induction of antihuman immunodeficiency virus activities in macrophages. Immunology 2010; 131:40–49.

This shows that TLR3 stimulation can confer HIV protection in macrophages through the upregulation of APOBEC3G and tetherin as well as HIV-inhibitory microRNAs.

38. Ogawa Y, Kawamura T, Kimura T, et al. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. Blood 2009; 113:5157–5166.

39•. Brichacek B, Vanpouille C, Kiselyeva Y, et al. Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One 2010; 5:e12831.

This study examines the effect of stimulating different TLRs on HIV susceptibility.

40. Trifonova RT, Doncel GF, Fichorova RN. Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob Agents Chemother 2009; 53:1490–1500.

41. Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009; 31:220–231.

42. Benakanakere MR, Li Q, Eskan MA, et al. Modulation of TLR2 protein expression by miR-105 in human oral keratinocytes. J Biol Chem 2009; 284:23107–23115.

43. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 2009; 106:2735–2740.

44••. Liu X, Zhan Z, Xu L, et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J Immunol 2010; 185:7244–7251.

This study suggests that inhibiting TLR signaling may have unwanted effects such as impairing innate responses or Ag-presenting capacity of dendritic cells.

45•. Hong B, Song X, Rollins L, et al. Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest 2011; 121:739–751.

This study describes a promising adjuvant that modulates innate immune responses.

46. Saphire A, Bobardt M, Gallay P. Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells. Immunol Res 2000; 21 (2–3):211–217.

47••. Daelemans D, Dumont J, Rosenwirth B, et al. Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Res 2010; 85:418–421.

This study shows that HIV can be inhibited using a CypA inhibitor, which may be developed further and used therapeutically.

48••. Shi J, Zhou J, Shah V, et al. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 2011; 85:542–549.

This study introduces a molecule that mimics the premature uncoating of HIV achieved by simian TRIM5α, which may have therapeutic potential.

49••. Singh R, Gaiha G, Werner L, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2011; 85:208–216.

This study demonstrates the HIV-protective properties of TRIM22, although its mechanisms of action are not clear.

50. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646–650.

51. Wang Y, Bergmeier L, Stebbings R, et al. Mucosal immunization in macaques upregulates the innate APOBEC 3G antiviral factor in CD4(+) memory T cells. Vaccine 2009; 27:870–881.

52•. Kim E, Bhattacharya T, Kunstman K, et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 2010; 84:10402–10405.

This study suggests that APOBEC3G can help generate viral sequence diversification and the evolution of beneficial viral variants.

53•. Sadler H, Stenglein M, Harris R, Mansky L. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010; 84:7396–7404.

This study raises the concern that APOBEC3G upregulation may raise HIV mutagenicity that leads to the evolution of immune escape and drug-resistant phenotypes.

54. Neil S, Zang T, Bieniasz P. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425–430.

55. Malim MH, Emerman M. HIV-1 accessory proteins – ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3:388–398.

56. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009; 29:569–580.

57. Khan M, Kao S, Miyagi E, et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 2005; 79:5870–5874.

58•. Albin J, Haché G, Hultquist J, et al. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol 2010; 84:10209–10219.

This study suggests that HIV can adapt to replicate efficiently in an environment where APOBEC3G is upregulated.

59•. Ma J, Li X, Xu J, et al. The cellular source for APOBEC3G's incorporation into HIV-1. Retrovirology 2011; 8:2.

This study investigates the intracellular regulation of APOBEC3G activity through active and inactive forms of the protein.

60•. Farrow M, Kim E, Wolinsky S, Sheehy A. NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G. J Biol Chem 2011; 286:2567–2577.

This study describes the potential mechanisms that regulate APOBEC3G transcription.

61. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. T Cell Host Microbe 2008; 3:245–252.

62•. Casartelli N, Sourisseau M, Feldmann J, et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 2010; 6:e1000955.

This study verifies tetherin's antiviral activity, and expands its known functions to include inhibition of cell–cell transmission.

63. Cao W, Bover L, Cho M, Wen X, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009; 206:1603–1614.

64•. Favre D, Mold J, Hunt P, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32–36.

This study shows that IDO mediates the reduction of Th17 T cells leading to the disruption of the mucosal barrier.

65. Manches O, Munn D, Fallahi A, et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 2008; 2008:10:3431–3439.

66••. Martinson J, Montoya C, Usuga X, et al. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother 2010; 54:871–881.

This study shows that chloroquine may be useful as a therapeutic agent in HIV-infected patients with chronic immune activation as it downregulates IFN and negative T-cell responses.

67••. Melki M, Saïdi H, Dufour A, et al. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk: a pivotal role of HMGB1. PLoS Pathog 2010; 6:e1000862.

This study describes an immune evasion strategy that may be targeted for HIV inhibition once its mechanisms have been fully elucidated. The HMBG1 inhibitor used, Glycyrrhizin is in clinical use for other purposes and is anti-inflammatory, making it a viable therapeutic candidate.

68•. Vieillard V, Fausther-Bovendo H, Samri A, et al. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Defic Syndr 2010; 53:564–573.

This study investigates what differences in NK-cell phenotype that aid in the control of HIV infection.

69•. Shah AH, Sowrirajan B, Davis ZB, et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010; 8:397–409.

This study deals with a HIV strategy to avoid NK-mediated lysis of infected cells.

70. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011; 11:176–186.

71. Herbeuvala J-P, Shearerb GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007; 123:121–128.

72•. Sabado R, O’Brien M, Subedi A, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010; 116:3839–3852.

This study describes hyperresponsiveness in mDCs and pDCs and indicates that they play a key role in chronic immune activation.

73. Blankson J. Control of HIV-1 replication in elite suppressors. Discov Med 2010; 9:261–266.

74•. Chang J, Lindsay R, Kulkarni S, et al. Polymorphisms in interferon regulatory factor 7 reduces interferon-α responses of plasmacytoid dendritic cells to HIV-1. AIDS 2011; 25:715–717.

This study elucidates the control of pDC IFN production by IRF-7. Further elucidation of the regulation of IFN production will be valuable for the control of chronic immune activation.

75. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82:5450–5459.

76. Alter G, Teigen N, Davis B, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106:3366–3369.

77•. Aldhamen Y, Appledorn D, Seregin S, et al. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. J Immunol 2011; 186:722–732.

This study describes an adjuvant that acts by activating dendritic cells and macrophages, which may be useful in a HIV vaccine.

78•. Strbo N, Vaccari M, Pahwa S, et al. Gp96(SIV)Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine 2011; 29:2619–2625.

This study suggests the use of a heat shock protein as an adjuvant to enhance mucosal vaccine responses.

79••. Abdool Karim Q, Abdool Karim S, Frohlich J, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168–1174.

This study indicates that mucosal administration of antiviral agents can confer protection against HIV.


HIV; innate; microbicides; therapeutics

© 2011 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.